Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Total Valuation
Sangamo Biosciences has a market cap or net worth of $156.17M. The enterprise value is $199.79M.
Market Cap$156.17M
Enterprise Value$199.79M
Share Statistics
Sangamo Biosciences has 336,494,480 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding336,494,480
Owned by Insiders1.60%
Owned by Institutions0.66%
Financial Efficiency
Sangamo Biosciences’s return on equity (ROE) is -4.30 and return on invested capital (ROIC) is -172.58%.
Return on Equity (ROE)-4.30
Return on Assets (ROA)-0.96
Return on Invested Capital (ROIC)-172.58%
Return on Capital Employed (ROCE)-1.86
Revenue Per Employee315.85K
Profits Per Employee-535.20K
Employee Count183
Asset Turnover0.57
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sangamo Biosciences is ―. Sangamo Biosciences’s PEG ratio is 0.03.
PE Ratio―
PS Ratio3.56
PB Ratio9.04
Price to Fair Value9.04
Price to FCF-3.05
Price to Operating Cash Flow-3.43
PEG Ratio0.03
Income Statement
In the last 12 months, Sangamo Biosciences had revenue of 57.80M and earned -97.94M in profits. Earnings per share was -0.49.
Revenue57.80M
Gross Profit57.80M
Operating Income-103.97M
Pretax Income-98.11M
Net Income-97.94M
EBITDA-89.09M
Earnings Per Share (EPS)-0.49
Cash Flow
In the last 12 months, operating cash flow was -76.16M and capital expenditures -240.00K, giving a free cash flow of -76.40M billion.
Operating Cash Flow-76.16M
Free Cash Flow-76.40M
Free Cash Flow per Share-0.23
Dividends & Yields
Sangamo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-80.51%
50-Day Moving Average0.57
200-Day Moving Average0.63
Relative Strength Index (RSI)44.04
Average Volume (3m)6.92M
Important Dates
Sangamo Biosciences upcoming earnings date is Feb 25, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
Sangamo Biosciences as a current ratio of 1.13, with Debt / Equity ratio of 119.69%
Current Ratio1.13
Quick Ratio1.13
Debt to Market Cap0.00
Net Debt to EBITDA0.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sangamo Biosciences has paid -167.00K in taxes.
Income Tax-167.00K
Effective Tax Rate<0.01
Enterprise Valuation
Sangamo Biosciences EV to EBITDA ratio is -2.18, with an EV/FCF ratio of -2.88.
EV to Sales3.36
EV to EBITDA-2.18
EV to Free Cash Flow-2.88
EV to Operating Cash Flow-2.90
Balance Sheet
Sangamo Biosciences has $30.53M in cash and marketable securities with $25.42M in debt, giving a net cash position of $5.10M billion.
Cash & Marketable Securities$30.53M
Total Debt$25.42M
Net Cash$5.10M
Net Cash Per Share$0.02
Tangible Book Value Per Share$0.11
Margins
Gross margin is 97.40%, with operating margin of -179.88%, and net profit margin of -169.45%.
Gross Margin97.40%
Operating Margin-179.88%
Pretax Margin-169.74%
Net Profit Margin-169.45%
EBITDA Margin-154.13%
EBIT Margin-170.33%
Analyst Forecast
The average price target for Sangamo Biosciences is $4.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.33
Price Target Upside841.30% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-37.13%
EPS Growth Forecast40.47%